Aurinia to Acquire Kezar for $6.955/Share Cash

Aurinia Pharma U.S., Inc., along with Aurinia Merger Sub, Inc. and Aurinia Pharmaceuticals Inc., has filed a Schedule TO tender offer statement for the acquisition of Kezar Life Sciences, Inc. The offer is to acquire all issued and outstanding Kezar shares.

Under the terms, Kezar shareholders will receive $6.955 per share in cash, without interest, plus one nontransferable contractual contingent value right (CVR) for each share. The filing references an Offer to Purchase dated April 13, 2026 and an Agreement and Plan of Merger dated March 30, 2026.